Explore more publications!

Latest News

Labels On
FILTER THE FEED
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
FILTER THE FEED
Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
FDA Approves Dupilumab for AFRS in Patients Aged ≥ 6 Years With Prior Surgery

FDA Approves Dupilumab for AFRS in Patients Aged ≥ 6 Years With Prior Surgery

Indeterminate Consultant Live
Owner: Mike Hennessy Jr.
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity

Indeterminate Consultant Live
Owner: Mike Hennessy Jr.
<![CDATA[Q&A: AI-predicted retinal function shows promise in geographic atrophy]]>

<![CDATA[Q&A: AI-predicted retinal function shows promise in geographic atrophy]]>

Indeterminate Modern Retina
Owner: Mike Hennessy Jr.
Conservative opposition to Trump drug pricing plan partly bankrolled by pharmaceutical industry

Conservative opposition to Trump drug pricing plan partly bankrolled by pharmaceutical industry

Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors

Rare diseases: FDA proposes new system to therapy approvals

Rare diseases: FDA proposes new system to therapy approvals

<![CDATA[The Effectiveness of TV Advertising for Pharma]]>

<![CDATA[The Effectiveness of TV Advertising for Pharma]]>

Oducado calls for stronger local pharma industry

Oducado calls for stronger local pharma industry

<![CDATA[FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer]]>

<![CDATA[FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer]]>

Indeterminate Cancer Network
Owner: Mike Hennessy Jr.
Sequencing non-incretin agents and framing obesity as a chronic disease

Sequencing non-incretin agents and framing obesity as a chronic disease

Indeterminate Consultant Live
Owner: Mike Hennessy Jr.
UBT251, A Triple Agonist, Delivers Up To 19.7% Mean Weight Loss in Phase 2 Trial

UBT251, A Triple Agonist, Delivers Up To 19.7% Mean Weight Loss in Phase 2 Trial

Indeterminate Consultant Live
Owner: Mike Hennessy Jr.
What the Polls Say about the Pharmaceutical Industry and Vaccines

What the Polls Say about the Pharmaceutical Industry and Vaccines

Right-wing Brownstone
Owner: American Brownstone Institute
Conservative opposition to Trump drug pricing plan partly bankrolled by pharmaceutical industry

Conservative opposition to Trump drug pricing plan partly bankrolled by pharmaceutical industry

Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors

Rare diseases: FDA proposes new system to therapy approvals

Rare diseases: FDA proposes new system to therapy approvals

<![CDATA[The Effectiveness of TV Advertising for Pharma]]>

<![CDATA[The Effectiveness of TV Advertising for Pharma]]>

Oducado calls for stronger local pharma industry

Oducado calls for stronger local pharma industry

<![CDATA[FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer]]>

<![CDATA[FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer]]>

Sequencing non-incretin agents and framing obesity as a chronic disease

Sequencing non-incretin agents and framing obesity as a chronic disease

UBT251, A Triple Agonist, Delivers Up To 19.7% Mean Weight Loss in Phase 2 Trial

UBT251, A Triple Agonist, Delivers Up To 19.7% Mean Weight Loss in Phase 2 Trial

FDA Approves Dupilumab for AFRS in Patients Aged ≥ 6 Years With Prior Surgery

FDA Approves Dupilumab for AFRS in Patients Aged ≥ 6 Years With Prior Surgery

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity

<![CDATA[Q&A: AI-predicted retinal function shows promise in geographic atrophy]]>

<![CDATA[Q&A: AI-predicted retinal function shows promise in geographic atrophy]]>

Show More

Video Stories

YouTube video thumbnail: If Food is Medicine, how About a Prescription for Blueberries?
Play
If Food is Medicine, how About a Prescription for Blueberries?
YouTube video thumbnail: How Japan Is Revolutionising Healthcare With Personalised Genetic Data and Targeted Exosome Therapy
Play
How Japan Is Revolutionising Healthcare With Personalised Genetic Data and Targeted Exosome Therapy
YouTube video thumbnail:  Zambia’s Toxic Legacy
Play
Zambia’s Toxic Legacy
YouTube video thumbnail: The Risks of Short Form Video to Our Brains
Play
The Risks of Short Form Video to Our Brains

Video Title

Press Releases

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

A. Nelson & Co. Ltd. - 720283 - 02/12/2026

A. Nelson & Co. Ltd. - 720283 - 02/12/2026

AQ USA Inc., d.b.a Ross Healthcare Inc. - 719517 - 02/12/2026

AQ USA Inc., d.b.a Ross Healthcare Inc. - 719517 - 02/12/2026

MedisourceRx - 717970 - 12/12/2025

MedisourceRx - 717970 - 12/12/2025

Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause

Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

A. Nelson & Co. Ltd. - 720283 - 02/12/2026

A. Nelson & Co. Ltd. - 720283 - 02/12/2026

AQ USA Inc., d.b.a Ross Healthcare Inc. - 719517 - 02/12/2026

AQ USA Inc., d.b.a Ross Healthcare Inc. - 719517 - 02/12/2026

MedisourceRx - 717970 - 12/12/2025

MedisourceRx - 717970 - 12/12/2025

Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause

Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause

Show More
Your brand’s story is being written — with or without you.
We’re the leading press release service for mid-sized businesses & organizations built for the AI era.
Learn more

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions